Menu
Not yet recruiting NCT06000670

Efficacy of Autologous Adipose Derived Stromal Vascular Fraction for Musculoskeletal Conditions

No phase Interventional Knee Osteoarthritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: stromal vascular fraction injection in the osteoarthritic knee.
Who it may be relevant to
Registry conditions: Knee Osteoarthritis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

clinical efficacy of autologous stromal vascular fraction SVF,for inflammatory and degenerative conditions of the knees

Detailed description

to evaluate the clinical effectiveness of point of care autologous adipose derived stromal vascular fraction (SVF) alone or in combination with exosomes,for inflammatory and degenerative conditions of the knees.

Interventions

  • Procedure stromal vascular fraction injection in the osteoarthritic knee
    stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.

Primary outcome measures

  • change in pain level [Time frame: 2 years]
Secondary outcome measures (1)
  • percentage cartilage thickness change [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • knee osteoarthritis any grade
  • knee chondromalacia grade 2 and above

Exclusion criteria

  • active HIV
  • pregnant women
  • Mental disease
  • severe cardio vascular disease
  • severe coagulation disorders
  • infected tissues
  • patients on other experimental studies within 3 months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06000670 · DHA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗